CC
FSTX

Caxton Corporation’s F-star Therapeutics, Inc. Common Stock FSTX Stock Holding History

Caxton Corporation’s Portfolio FSTX Stock Details FSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-5,969
Closed -$82K – 49
2019
Q3 		$82K Buy
5,969
+14
+0.2% +$231 0.09% 40
2019
Q2 		$88K Buy
5,955
+26
+0.4% +$696 0.1% 31
2019
Q1 		$249K Buy
5,929
+670
+13% +$28.2K 0.23% 20
2018
Q4 		$219K Buy
5,259
+12
+0.2% +$540 0.27% 22
2018
Q3 		$253K Buy
+5,247
New +$263K 0.23% 23

Other funds holding FSTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TA
Tiedemann Advisors New York $2.33B AUM 15.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HP
Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Caxton Corporation's FSTX Position: Q4 2019 in Review

Caxton Corporation sold out of F-star Therapeutics, Inc. Common Stock (FSTX) in Q4 2019, closing a stake of 5,969 shares — an estimated $82K sold.

Caxton Corporation first reported a position in FSTX in Q3 2018 and held it in 5 quarters. The position peaked at $253K in Q3 2018. 31 funds tracked by Wall St. Rank hold FSTX as of Q4 2019.

  • Caxton Corporation reported no remaining F-star Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Caxton Corporation sold 5,969 F-star Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $82K.
  • Caxton Corporation first reported a position in F-star Therapeutics, Inc. Common Stock in Q3 2018 and held it in 5 quarters.
  • Caxton Corporation's F-star Therapeutics, Inc. Common Stock position peaked at $253K in Q3 2018.
  • 31 funds tracked by Wall St. Rank held F-star Therapeutics, Inc. Common Stock as of Q4 2019.

Based on Caxton Corporation's 13F filing for Q4 2019, filed 14 Feb 2020.